Animals were transplanted as described in Materials and Methods, and survival and clinical GVHD scores were monitored for 100 days (n = 6 for syngeneic control group; n = 9 for the MCMV treated syngeneic group, n = 18 for allogeneic control group and n = 19 for the MCMV treated allogeneic group). Data are combined from two identical experiments. (*p,0.005,**p,0.001). (C ) Detection of gene D2Mit265 PCR products for BALB/c (139 bp) and B10.D2 (103 bp) was used to determine donor cell chimerism in the spleen. doi:10.1371/journal.pone.0061841.grecipients receiving B10.D2 donor cells demonstrated at least 80 donor chimerism, consistent with successful donor cell engraftment.of the MCMV allogeneic group (figure 3). On the basis of.Ed, mortality was still low (8.3 ). In 1516647 contrast, allogeneic MCMV infected animals showed increased mortality (26.3 ) along with significantly increased clinical GVHD scores (figure 2A ).Statistical analysisAll values are expressed as the mean 6 SEM. Survival curves were plotted and compared by log-rank analysis. Statistical comparisons between groups were completed using an unpaired t test. P,0.05 was considered statistically significant.Results Infection with MCMV Smith strain successfully mounts anti-MCMV IgG seroconversionRecipient mice were either infected with MCMV Smith strain or mock treated as described in Materials and Methods. MCMV infection was well tolerated and no MCMV-related death occurred during the observation period of 25 weeks. MCMV treated animals showed no difference in weights and clinical scores when compared to mock infected (Fig. 1A). Prior to subsequent transplant, animals were analyzed for MCMV seroconversion by ELISA in order to ensure successful MCMV infection. As shown in figure 1B, anti MCMV IgG antibodies were detected in all mice treated with the virus, and as expected, none of the mock treated animals was tested IgG positive. None of the animals was clinically sick at this time point and accordingly considered to be latently infected.Chimerism